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Summary Phase II studies have confirmed gemcitabine (GEMZARO) to be an active single agent in treating non-small-cell lung cancer
(NSCLC), with response rates averaging 21%. Toxicity, including myelosuppression, is mild, making gemcitabine an attractive agent to
consider in combination regimens. Most experience with gemcitabine in combination has been with cisplatin. Five phase 11 studies have been
performed using different scheduling and dosage regimens. Response rates varied from 38% to 54% and median survival was 8.4-14.3
months. This combination was well tolerated and required minimal hospitalization. Haematological toxicity of short duration was dose limiting,
with thrombocytopenia WHO grades 3/4 in 16-52% of patients and neutropenia in 36-58%. Nausea and vomiting occurred with cisplatin.
Ifosfamide has been combined with gemcitabine in a phase I/Il study. Based on phase data, ifosfamide 1500 mg m-2 day-' was chosen for
the phase 11 study. The overall response rate was 32%. Toxicity was mild and was mainly related to short-lived myelosuppression. In
summary, the favourable toxicity profile of single-agent gemcitabine enables its safe combination with other active agents in the treatment of
NSCLC. The combination with cisplatin appears particularly encouraging, and a phase IlIl study comparing this combination with standard
chemotherapy regimens is planned. The combination of gemcitabine with radiotherapy is also under investigation.
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Lung cancer is now the most common cause of cancer death in
North America in both men and women, having recently overtaken
breast cancer in women. The three main histological subtypes of
non-small-cell lung cancer (NSCLC) - squamous, adenocarci-
noma and large cell -account for over 80% ofthe 170 000 cases of
bronchial carcinoma diagnosed each year in the USA. It is
predominantly a disease of elderly patients, many of whom have
concomitant respiratory and cardiovascular pathology.
Until recently, only four agents with a response rate of more
than 15% in NSCLC were available: cisplatin, ifosfamide, vinde-
sine and mitomycin C. The toxicities ofthese drugs are significant
and, as the survival time for such patients has typically been short,
their value has been questioned and chemotherapy has usually
been avoided. In NSCLC, it is important that treatment regimens
are well tolerated and require the minimum amount ofhospitaliza-
tion and, as a result, new agents with greater activity and fewer
side-effects have been sought in recent years.
NEW APPROACHES TO THE TREATMENT OF
NSCLC
Surgery is the only curative treatment for NSCLC. Unfortunately,
over 70% of patients present with advanced stages of disease and
are inoperable. In these cases, chemotherapy can provide useful
palliation of symptoms and modest prolongation of survival.
Several promising new agents have recently become available and
appear to offer advantages over established therapy in a variety of
solid tumours, either in terms ofgreater activity or reduced toxicity.
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The camptothecin analogues, topotecan and irinotecan, act by
inhibiting topoisomerase 1, an enzyme involved in DNA replica-
tion. Topoisomerase 1 binds to DNA during replication and causes
a single-strand break in the helix, allowing relaxation ofthe tightly
coiled configuration. Once relaxation has taken place, the nick is
repaired and the enzyme dissociates from the helix. Topoisomerase
1 inhibitors prevent the resealing of the DNA strand, thus
preventing DNA replication and causing cell death. Irinotecan has
shown impressive response rates in clinical trials, particularly in
patients with colorectal cancer (Armand et al, 1995).
Another group of agents that have shown activity in the treat-
ment of solid tumours are the taxoids. These prevent cell division
by binding to the microtubules formed during this process,
forming very stable complexes and preventing mitosis. Paclitaxel
has demonstrated significant single-agent activity against NSCLC
in clinical trials, with response rates of24% (Murphy et al, 1993).
Antimetabolites are agents that interfere with cell function as a
result of their structural resemblance to compounds essential for
cell metabolism (Clarke et al, 1991). As information on nucleotide
synthesis in dividing cells has emerged, new targets for
chemotherapeutic intervention have been identified, leading to the
development of drugs with greater selectivity for tumour cells.
Such agents can act in a variety of ways. Methotrexate, one ofthe
earliest antimetabolites discovered, is an inhibitorofdihydrofolate
reductase and leads to depletion of reduced folates within the cell
(Jolivet et al, 1983). The thymidylate synthase inhibitors, another
class of antimetabolite, lead to decreased thymidine biosynthesis
and, ultimately, to cell death (Rustum et al, 1997).
Nucleoside analogues are also under active investigation
(Perigaud et al, 1992). These are agents that resemble the nucleo-
sides used in DNA and RNA synthesis. One example is cytosine
arabinoside, an analogue ofthe nucleoside deoxycytidine, which is
used to treat adult myelogenous leukaemia. It has no activity
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Table 1 Gemcitabine-cisplatin phase 11 trials: patient characteristics and schedules used
Study UK/France South Africa Italy USA Spain
Gemcitabine dose (mg m-2) 1000 1000 1000 1000 1200
(days 1,8,15, every 28)
Cisplatin dose (mg m-2) 100 100 100 100 100
(schedule) (day 15) (day 15) (day 2) (day 1) (day 15)
Patients entered/evaluable 60/52 53/50 48/48 30/26 40/40
Age range (median)(years) 39-74 (59) 35-74 (56) 37-70 (60) 37-74 (62) (64)
Stage III/IV 41/19 33/20 21/5 5/21 11/8
Histology N/A
Squamous 30 26 22 10
Adenocarcinoma 20 20 21 11
Large cell 9 3 5 6
Unspecified 1 4 0 3
N/A, data not available.
against solid tumours (Keating et al, 1982). Gemcitabine is a diflu-
orinated analogue of cytosine arabinoside, which differs from the
parent compound in having increased membrane permeability and
affinity for deoxycytidine kinase (Heinemann et al, 1988). It is
incorporated into DNA in place of deoxycytidine, and one further
nucleoside is incorporated before DNA synthesis is terminated.
This mechanism, known as 'masked chain termination', appears to
prevent excision repair of the altered DNA sequence by proof-
reading enzymes and thus overcomes one important potential
mechanism for developing resistance. In vivo, gemcitabine has
shown high activity against a range ofhuman xenografts, including
breast, colon, pancreatic and lung cancers (Merriman et al, 1996).
CLINICAL TRIALS OF GEMCITABINE IN NSCLC
Phase I and II studies have shown that gemcitabine has single-
agent activity in the treatment of NSCLC, with average response
rates of 20% (Kaye, 1994). The drug is well tolerated, with few
serious side-effects. Those that were seen included mild
leucopenia and thrombocytopenia, skin rashes and transient
increases in transaminase levels. These findings make gemcitabine
an excellent candidate for combination with other anti-cancer
agents, with the hope of producing increased activity and accept-
able toxicity.
COMBINATION OF GEMCITABINE AND
CISPLATIN
Cisplatin is currently the most frequently used agent incorporated
into chemotherapy regimens. Its use is associated with a modest
survival benefit compared with best supportive care. It is thought
to work by forming inter- and intra-strand cross-links with DNA
(Roberts and Pascoe, 1972). Unfortunately, tumour resistance
develops, and an important mechanism appears to be the recogni-
tion and excision of cross-links by proof-reading enzymes.
Preclinical experiments have shown that the combination of
cisplatin and gemcitabine has synergistic activity against human
ovarian and head and neck squamous cancer cell lines in mice,
with a variable effect that depends on the schedule used (Peters et
al, 1995). Clinical trials have thus been initiated to evaluate the
combination in humans, and additional combinations may be
worth exploring to fully exploit the experimental synergy.
Table 2 Gemcitabine-cisplatin phase 11 trials: toxicities
Patients (%)
Toxicity WHO Day 2 Day 15 Day 15 Day 15
grade 3/4 Italy UK/France South Africa Spain
Thrombocytopenia 52 21 21 16
Neutropenia 36 58 58 56
Transaminases 0 4 N/A N/A
Nausea/vomiting 27 64 64 28
Alopecia 6 8 8 N/A
N/A, data not available.
Table 3 Gemcitabine-cisplatin phase 11 trials: responses and survival
UK/ South Italy USA Spain
France Africa
Evaluable for response (patients) 52 50 48 26 40
Complete response (patients) 0 2 1 1 0
Partial response (patients) 20 24 25 10 19
Overall response rate (%) 38 52 54 42 48
Median survival (months) 10.2 13 14.3 8.4 10.4
1-Year survival (%) 40 61 59 37 35
Five phase II trials have investigated the effect ofscheduling on
toxicities and efficacy in NSCLC. In four of these studies, gem-
citabine (1000 mg m-2) was given on a weekly basis for 3 weeks
and cisplatin (100 mg m-2) was given once during the 28-day
cycle, on different days in three trials. The schedules and patient
characteristics for all five trials are summarized in Table 1.
In a sequential phase I1II study carried out in France and the UK
(Steward et al, 1996), patients with inoperable, progressive
NSCLC were given gemcitabine (1000 mg m-2) on days 1, 8
and 15 of a 28-day cycle. Escalating doses of cisplatin (60-
100 mg m-2) were administered on day 15 of each cycle, immedi-
ately after the gemcitabine injection. The phase I portion of the
trial identified the maximum-tolerated dose of cisplatin as
100 mg m-2. The study was expanded into a full phase II trial
including 60 patients. Of the 52 evaluable patients, partial
responses were seen in 20, for an overall response rate of 38%.
Neutropenia and thrombocytopenia, the most commonly observed
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side-effects (Table 2), were short lived and uncomplicated. Grade
3 nausea and vomiting occurred on day 15 in 50% of patients, but
was not any worse than that seen with cisplatin alone. No renal or
hepatotoxicities were seen in these patients and alopecia was
uncommon. The median survival was 10.2 months and the I-year
survival rate was 40% (Sandler et al, 1996).
In a similar study carried out in South Africa by Abratt and
colleagues (1997), 53 patients were given gemcitabine
(1000mg m-2) on days 1, 8 and 15 of a 28-day cycle. Cisplatin
(100mg m-2) was administered on day 15 of each cycle. The
median number ofcycles administered was four (range one to six).
Fifty patients were evaluable for response and 53 for toxicity. The
main toxicities observed were haematological, in particular
neutropenia and thrombocytopenia. WHO grades 3 and 4
neutropenia were seen in 20 and 10 patients, respectively, and
grades 3 and 4 thrombocytopenia in nine and four patients respec-
tively. Other toxicities are summarized in Table 2. Complete
responses were seen in two patients and partial responses in 24, for
an overall response rate of52%. The median survival duration was
13 months and the 1-year survival rate was 61 %.
Two other phase II studies have been carried out that investi-
gated the effect of giving cisplatin on different days of the
schedule. The first of these involved 48 patients with stage III or
IV unresectable NSCLC and was carried out in several centres in
Italy (Crin6 et al, 1997). Cisplatin (100 mg m-2) was given on day
2 of each cycle. Haematological toxicities were the most
frequently observed side-effects; WHO grade 3/4 thrombocyto-
penia was seen in 52% ofpatients and grade 3 or 4 neutropenia in
36%. Of 48 evaluable patients, one complete and 25 partial
responses were observed, giving an overall response rate of 54%.
The median response duration was 14.3 months. Ten responses
lasting longer than 60 weeks were seen.
The final phase II trial using gemcitabine 1000 mg m-2 was
carried out in the USA by the Hoosier Oncology Group (Sandler et
al, 1995). Cisplatin (100mg m-2) was given on day 1 of a 28-day
cycle to 30 patients, 26 of whom were evaluable for response.
Toxicities were mainly haematological, and it was frequently neces-
sary to omit gemcitabine on days 8 and/or 15 of the cycle. One
complete and ten partial responses were documented, giving an
overall response rate of42%. The median survival was 8.4 months
and 37% ofpatients were alive at 1 year (Sandler et al, 1996).
A Spanish study investigated the effects of higher doses of
gemcitabine in combination with 100 mg m-2 cisplatin in patients
with advanced NSCLC (Anton et al, 1997). Gemcitabine
(1200 mg m-2) was administered on days 1, 8 and 15, and cisplatin
was given on day 15. All 40 patients were evaluable for response
and toxicity. Toxicities were mainly haematological, with grade
3/4 thrombocytopenia seen in 56% of cycles. Partial responses
were seen in 19 patients, for an overall response rate of 48%. The
median survival was 10.4 months and the 1-year survival rate
35%. Responses and survival rates for all trials are summarized in
Table 3.
In order to investigate the effects ofescalating the dose of gem-
citabine and fractionating the cisplatin administration, a phase 1/11
study was carried out in 50 patients in Canada by Shepherd et al
(1996). Cisplatin was given with each of the weekly doses of
gemcitabine. This study established that 1500 mg m-2 gemcitabine
and 30 mg m-2 cisplatin could be given weekly to patients without
-unacceptable side-effects. Nausea and vomiting were less severe
than seen in the other studies, in which higher doses of cisplatin
had been administered. Granulocytopenia and thrombocytopenia
were, however, frequently observed, and dose reductions were
often required. Ten partial responses were seen, giving a response
rate of 36%. A phase II study is underway to investigate this
regimen further.
In a randomized phase III trial, Cardenal et al (1997) have
studied the combination of gemcitabine and cisplatin vs cisplatin
and etoposide. A total of 136 patients were enrolled and random-
ized to receive either gemcitabine (1250 mg m-2) on days I and 8
or etoposide (100 mg m-2) on days 1-3 of a 21-day cycle. Cisplatin
(100 mg m-2) was given to all patients on day 1 of each cycle. The
preliminary response rate for the gemcitabine arm is 48% and the
response rate in the etoposide arm is 22%. Toxicities were, in
general, less severe in patients receiving the gemcitabine and
cisplatin combination, with the exception of grade 3 and 4
thrombocytopenia, which occurred in 20% of patients on this arm,
as opposed to 3.5% of patients receiving the etoposide-cisplatin
combination.
COMBINATION OF GEMCITABINE WITH OTHER
AGENTS AND WITH RADIOTHERAPY
Ifosfamide is frequently used in the treatment of NSCLC
(Schoenike and Dana, 1990). As its mechanism ofaction and toxi-
city profile differ from those of gemcitabine, the two drugs were
combined in a phase I/II study (Eberhard et al, 1995). In the phase
I portion, gemcitabine (1000 mg m-2) was given on days 1, 8 and
15 of a 28-day cycle and escalating doses of ifosfamide
(1200-1800 mg m-2) were given to sequential cohorts on days
8-12. Partial responses were seen, and the dose of ifosfamide
identified for phase II investigation was 1500 mg m-2. Of the 56
patients enrolled, 50 were evaluable for toxicity and response
(Manegold et al, 1996). Grade 3 and 4 neutropenia were seen in
32% and 15% of patients, respectively, and grade 3 and 4 throm-
bocytopenia in 16% and 3% ofpatients. Grade 3 alopecia occurred
in 57% of patients. Preliminary results suggest that partial
responses were seen in 16 patients (32%), suggesting that the
combination ofgemcitabine and ifosfamide has promising activity
in the treatment of NSCLC.
Vinorelbine is another agent active against NSCLC. Krajnik and
colleagues (1997) have studied the combination of gemcitabine
and vinorelbine in a dose-finding phase I trial in 33 patients with
advanced disease. Doses of gemcitabine (1000 mg m-2) and
vinorelbine (25 mg m-2) have not yet given rise to dose-limiting
toxicities and investigations are continuing to find the maximum-
tolerated dose.
Gemcitabine is a potent radiation sensitizer, with a cytotoxicity
enhancement ratio of 1.8 measured in in vitro studies in human
colon carcinoma HT-29 cells (Lawrence et al, 1996). The gem-
citabine concentrations necessary to induce enhanced sensitivity to
radiation were significantly lower than those required to produce
direct cytotoxicity (Shewach et al, 1994). This was particularly
apparent in pancreas, colorectal, breast and non-small-cell lung
cancer cell lines. A phase II trial was designed that combined irra-
diation (up to 60 Gy) over 6 weeks with weekly injections of
gemcitabine (1000 mg m-2) in patients with stage III NSCLC
(Goor et al, 1996). Eight patients had been recruited when a toxic
death resulted in premature termination of the study. Severe side-
effects were seen in these patients who had received large doses of
both gemcitabine and radiation. Phase I trials are ongoing, using
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lower doses of radiation and gemcitabine, to assess the safety and
efficacy of this regimen.
The combination of gemcitabine, cisplatin and vinorelbine has
been studied in a randomized phase II trial in patients with
advanced stage IIIb/IV NSCLC (Comella et al, 1997). On one arm,
gemcitabine (1000 mg m-2) and cisplatin (50 mg m-2) were given
on days I and 8 every 3 weeks, combined with vinorelbine
(25 mg m-2). On the second arm, patients were treated with a
combination ofcisplatin, epirubicin, vindesine and lonidamine. Of
the 42 evaluable patients in the gemcitabine arm, one complete
response and 25 partial responses were seen, for an overall
response rate of 62% (95% CI 46-76%). In the control arm, 37 of
the 50 enrolled patients were evaluable for response. Three
complete responses and ten partial responses were reported, giving
an overall response rate of35% (95% CI 20-52%). Toxicities were
manageable in the gemcitabine arm. This combination is highly
effective and will be the subject of a phase III trial.
A phase I/II trial is also underway that will assess the activity of
a combination of gemcitabine and carboplatin in NSCLC and,
although results are preliminary, this combination appears to be
well tolerated (Carmichael et al, 1995).
CONCLUSION
Gemcitabine, a nucleoside analogue with a novel mechanism of
action and single-agent activity against NSCLC, has been used in
several different combination regimens in NSCLC. Its use with
cisplatin appears to have a significant advantage compared with
historical single-agent studies, with response rates of 32-54%,
depending on the doses and schedule used. One-year survival rates
at 35-61% are particularly encouraging.
The inclusion of ifosfamide in combination therapy has also
been associated with an improved response rate (32%) compared
with the use of either gemcitabine or ifosfamide as single agents.
Trials are also ongoing that will assess the effect ofgemcitabine in
combination with carboplatin, vinorelbine and radiotherapy.
While the results from all these trials are promising, comparisons
need to be made with other combinations currently in use, such as
the mitomycin-C-ifosfamide-cisplatin (MIC) regimen (Crin6 et al,
1995). Phase III randomized trials are now underway that will
compare the gemcitabine-cisplatin (day 2) combination with MIC,
as well as with single-agent cisplatin. The results will provide
important information on the role ofgemcitabine in this disease and
will hopefully confirm its value both in terms of improving the
activity of existing agents and also in improving survival and
quality oflife. Its mechanisms ofaction and low toxicity make it an
ideal candidate forconsideration in other combinations, and several
phase II studies are currently underway. The high activities
reported for many ofthe regimens in advanced disease clearly hold
great promise for consideration of their use in the neoadjuvant and
adjuvant settings. Major advances in the treatment of NSCLC
could be made if the results of surgery are improved or if more
patients could be down-staged and become operable; it is to be
hoped that the availability of gemcitabine will make an important
contribution to advances being made with these approaches.
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